WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes. TC-6987 is a modulator of the alpha7 neuronal nicotinic receptor and was discovered by Targacept scientists using Pentad™, the company’s proprietary drug discovery platform.
